Cytotoxicity to macrophages of tetrandrine, an antisilicosis alkaloid, accompanied by an overproduction of prostaglandins

Biochemical Pharmacology

Volumn 53, Issue 6, 1997, Pages 773-782

  Pang, Linhua ^a,b   Hoult, J R S ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

bisbenzylisoquinoline alkaloids; cyclo oxygenase 2; inducible nitric; macrophages cytotoxicity; nitric oxide; oxide synthase; prostaglandin E2; tetrandrine; Western blot

Indexed keywords

ALKALOID; GAMMA INTERFERON; INDOMETACIN; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PROSTAGLANDIN E2; TETRANDRINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; GUINEA PIG; IN VITRO STUDY; LUNG ALVEOLUS; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ALKALOIDS; ANIMALS; BENZYLISOQUINOLINES; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; ISOENZYMES; MACROPHAGES; MICE; NITRIC OXIDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SILICOSIS; TUMOR NECROSIS FACTOR-ALPHA; VERAPAMIL;

EID: 0030909069     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00817-9     Document Type: Article

References (48)

1. Schiff PL, Bisbenzylisoquinoline alkaloids. J Nat Prod 50: 529-599, 1987.
2. Jiangsu New Medical College, A Compendium of Chinese Medicines. Hong Kong: Shanghai Scientific and Technological Press [text in Chinese], 1979.
3. Li QL, Xu YH, Zhon ZH, Chen XW, Huang XG, Chen SL and Zhan CX, The therapeutic effect of tetrandrine on silicosis. Chin J Tuberc Res Dis 4: 321-328, 1981.
4. Yu XF, Zou CG and Lih MB, Observations of the effect of tetrandrine on experimental silicosis of rat. Ecotoxicol Environ Safety 7: 306-312, 1983.
5. Liu BC, Zou CG and Li YR, Studies of the contents of glycosaminoglycans from lungs of silicotic rats and tetrandrinetreated rats. Ecotoxicol Environ Safety 7: 323-329, 1983.
6. Sutter MC and Wang YX, Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc Res 27: 1891-1901, 1993.
7. 2+ mobilization in vascular smooth muscle: tetramethylpyrazine and tetrandrine. Stem Cells 12: 64-67, 1994.
8. King VF, Garcia ML, Himmel D, Reuben JP, Lam YKT, Pan JX, Han GQ and Kaczorowski GJ, Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin. J Biol Chem 263: 2238-2244, 1988.
9. Liu QY, Karpinski E and Pang PKT, Tetrandrine inhibits both T and L calcium channel currents in ventricular cells. J Cardiovasc Pharmacol 20: 513-519, 1992.
10. + channels. Life Sci 56: 295-306, 1995.
11. Leung YM, Kwan CY and Loh TT, Dual effects of tetrandrine on cytosolic calcium in human leukaemic HL-60 cells: intracellular calcium release and calcium entry blockade. Br J Pharmacol 113: 767-774, 1994.
12. Kondo Y, Takano F and Hojo H, Inhibitory effect of bisben-zylisoquinoline alkaloids on nitric oxide production in activated macrophages. Biochem Pharmacol 46: 1887-1892, 1993.
13. Likhitwitayawuid K, Angerhofer CK, Cordell GA, Pezzuto JM and Ruangrungsi N, Cytotoxic and antmalarial bisbenzylisoquinoline alkaloids from Stephania erecta. J Nat Prod 56: 30-38, 1993.
14. Lin LZ, Shieh HL, Angerhofer CK, Pezzuto JM, Cordell GA, Xue L, Johnson ME and Ruangrungsi N, Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Cycled barbata. J Nat Prod 56: 22-29, 1993.
15. Marshall SJ, Russell PF, Wright CW, Anderson MM, Phillipson JD, Kirby GC, Warhurst DC and Schiff PL, In vitro antiplasmodial, antiamoebic and cytotoxic activities of a series of bisbenzylisoquinoline alkaloids. Antimicrob Agents Chemother 38: 96-103, 1994.
16. 2- channel function and drug action. Trends Pharmacol Sci 16: 43-49, 1995.
17. Gardner CR, Laskin JD and Laskin DL, Platelet-activating factor-induced calcium mobilization and oxidative metabolism in hepatic macrophages and endothelial cells. J Leukocyte Biol 53: 190-196, 1993.
18. 2+ requirement for optimal lipid peroxidation of low density lipoprotein by activated human monocytes. J Clin Invest 91: 1499-1506, 1993.
19. Hackshaw KV and Shi Y, Fibroblast growth factors mobilize peritoneal macrophage intracellular calcium. Life Sci 54: 661-670, 1994.
20. Bates PJ, Ralston NVC, Vuk-Pavlovich Z and Rohrbach MS, Calcium influx is required for tannin-mediated arachidonic acid release from alveolar macrophages. Am J Physiol 268: L33-L40, 1995.
21. Daugherty A, Rateri DL, Schonfild G and Sobel BE, Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br J Pharmacol 91: 113-118, 1987.
22. Dushkin Ml and Schwartz YS, Effect of verapamil and nifedipine on cholesteryl ester metabolism and low-density lipoprotein oxidation in macrophages. Biochem Pharmacol 49: 389-397, 1995.
23. Mak T and Weglicki WB, Comparative antioxidant activities of propranolol, nifedipine, verapamil, diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 66: 1449-1552, 1990.
24. Tsuruo T, Circumvention of drug resistance with calcium channel blockers and monoclonal antibodies. Cancer Treat Res 48: 73-95, 1989.
25. Pastan I, Willingham MC and Gottesman M, Molecular manipulations of the multidrug transporter: a new role for transgenic mice. FASEB J 5: 2523-2528, 1991.
26. 2 synthase (cy-clooxygenase) in human monocytes. J Biol Chem 265: 16737-16740, 1990.
27. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D and Hwang D, Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 267: 25934-25938, 1992.
28. Akarasereenont P, Mitchell JA, Appleton I, Thiemermann C and Vane JR, Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol 113: 1522-1528, 1994.
29. Egan RW, Paxton J and Kuehl FA, Mechanism for irreversible self-deactivation of prostaglandin synthetase. J Biol Chem 251: 7329-7335, 1976.
30. Hemler ME and Lands WEM, Evidence for a peroxideinitiated free radical mechanism of prostaglandin biosynthesis. J Biol Chem 255: 6253-6261, 1980.
31. Peters-Golden M and Shelly C, The oral gold compound auranofin triggers arachidonate release and cyclooxygenase metabolism in the alveolar macrophage. Prostaglandins 36: 773-786, 1988.
32. 2 in mouse macrophages. J Leukocyte Biol 59: 329-335, 1993.
33. Bondeson J and Sundler R, Auranofin inhibits the induction of interleukin l β and tumor necrosis factor mRNA in macrophages. Biochem Pharmacol 50: 1753-1759, 1993.
34. 2 activities in resident mouse peritoneal macrophages. Biochem J 197: 427-433, 1981.
35. 1 macrophage-like cell line. Arch Biochem Biophys 238: 247-258, 1985.
36. 1 macrophage-like cell line. J Biol Chem 263: 3079-3085, 1988.
37. 2 from a macrophage cell line, RAW 264.7. Biochim Biophys Acta 963: 476-492, 1988.
38. 2 hydrolysing arachidonoyl-phospholipids in mouse peritoneal macrophages. FEBS Lett 48: 51-56, 1989.
39. 2 in mouse spleen and the macrophage cell line J774. Eur J Biochem 202: 873-880, 1991.
40. 2 in the pathobiology of disease. Lab Invest 55: 391-404, 1986.
41. Piguet PF, Pulmonary fibrosis induced by silica, asbestos and bleomycin. In: Xenobiotics and inflammation. (Ed. Schook LB and Laskin DL) pp. 283-300. San Diego, Academic Press, 1994.
42. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 263: 5380-5384, 1988.
43. 2-induced suppression. J Immunol 142: 4346-4350, 1989.
44. 2 and immunomodulation with indomethacin. J Immunol 151: 2142-2149, 1993.
45. Zeng XM, Martin GP and Marriott C, Tetrandrine delivery to the lung: The optimisation of albumin microsphere preparation by central composite design. Int J Pharm 109: 135-145, 1994.
46. Castranova V, Kang JH, Ma JK, Mo CO, Malanga CJ and Moore MD, Effects of bisbenzylisoquinoline alkaloids on alveolar macrophages: correlation between binding affinity, inhibitory potency and antifibrotic potential. Toxicol Appi Pharmacol 108: 242-252, 1991.
47. Castranova V, Kang JH, Moore MD, Pailes WH, Frazer DC and Schwegler-Berry D, Inhibition of stimulant-induced activation of phagocytic cells with tetrandtine. J Leukoc Biol 50: 412-422, 1991.
48. Ma JK, Mo CG, Malanga CJ and Castranova V, Binding of bisbenzylisoquinoline alkaloids to phosphatidylcholine vesicles and alveolar macrophages: relationship between binding affinity and antifibrogenic potential of these drugs. Exp Lung Res 17: 1061-1071, 1991.